PAVmed Inc. Reports Q2 2025 Results: Revenue at $1.2 Million, GAAP Net Loss of $13.3 Million, EPS at $(0.74); Adjusted Loss at $1.8 Million, EPS at $(0.11)

<a href="https://laohu8.com/S/PAVM">PAVmed Inc.</a> Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Revenue at $1.2 Million, GAAP Net Loss of $13.3 Million, EPS at $(0.74); Adjusted Loss at $1.8 Million, EPS at $(0.11)

PAVmed Inc., a diversified commercial-stage medical technology company, reported financial results for the second quarter of 2025. Lucid Diagnostics Inc., a subsidiary of PAVmed, processed 2,756 EsoGuard tests during the quarter, generating $1.2 million in revenue. This marks a significant milestone for the company as it pushes forward with its strategic goals. Additionally, Lucid has secured a meeting on September 4 to discuss Medicare Local Coverage Determination for EsoGuard. Veris Health Inc., another PAVmed subsidiary, completed its second-quarter financing, which allowed it to relaunch the development of its implantable physiological monitor. Veris is taking integration steps to commence the commercial phase in partnership with OSU-The James. These developments reflect PAVmed's strategy to stabilize its corporate structure and strengthen its balance sheet, positioning it as a diversified commercial life sciences entity with multiple independently-financed subsidiaries operating under a shared services model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-023729), on August 14, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

老虎證券

PAVmed Inc. Reports Q2 2025 Results: Revenue at $1.2 Million, GAAP Net Loss of $13.3 Million, EPS at $(0.74); Adjusted Loss at $1.8 Million, EPS at $(0.11)

熱議股票